Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis
Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis
复制标题
辅助经动脉化疗栓塞不影响合并肝细胞癌和胆管癌患者治愈性切除后的无复发或总生存：倾向评分匹配分析
DOI：
10.1186/s12885-020-07138-z
复制
发表时间：
2020-07-10
期刊：
影响因子：
3.8
通讯作者：
Shi, Ying-Hong
中科院分区：
文献类型：
--
作者：
Liu, Wei-Ren;Tian, Meng-Xin;Shi, Ying-Hong
BackgroundThe prognosis of patients with combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma (CHC) is usually poor, and effective adjuvant therapy is missing making it important to investigate whether these patients may benefit from adjuvant transarterial chemoembolization (TACE). We aimed to evaluate the efficiency of adjuvant TACE for long-term recurrence and survival after curative resection before and after propensity score matching (PSM) analysis.MethodsIn this retrospective study, of 230 patients who underwent resection for CHC between January 1994 and December 2014, 46 (18.0%) patients received adjuvant TACE. Univariate and multivariate regression analyses were used to identify the independent predictive factors of survival. Cox regression analyses and log-rank tests were used to compare overall survival (OS) and disease-free survival (DFS) between patients who did or did not receive adjuvant TACE.ResultsA total of 230 patients (mean age 52.211.9years; 172 men) were enrolled, and 46 (mean age 52.7 +/- 11.1years; 38 men) patients received TACE. Before PSM, in multivariate regression analysis, gamma -glutamyl transpeptidase (gamma -GT), tumour nodularity, macrovascular invasion (MVI), lymphoid metastasis, and extrahepatic metastasis were associated with OS. Alanine aminotransferase (ALT), MVI, lymphoid metastasis, and preventive TACE (HR: 2.763, 95% CI: 1.769-4.314, p
